Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The consistency of the safety profile across short-term and long-term trials suggests that AOD-9604 does not produce cumulative toxicity or delayed adverse effects that emerge only with chronic administration
However, the largest Phase IIb trial involving 536 participants failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading to development termination in 2007
Peptides like 5-Amino-1MQ can also play a role in fighting bacteria and maintaining skin health
Cyanocobalamin, whilst still used in some settings, is cleared from the body more rapidly, typically requiring more frequent administration
Regular injections ensure that levels remain stable, whereas infrequent injections may result in declining B12 levels over time
US$ 24.80
US$ 28.74
US$ 26.69
